에 대한 최신 뉴스 Teladoc Health (NYSE:TDOC) 주식

TELADOC HEALTH INC

Teladoc Health

Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.

ASTSpaceMobile.Screenshotvideo

Equities

Mid Cap

News

Movers

Tech

Trading Ideas

ASTS

IREN

MGNI

OKLO

TDOC

VNET

이 10개 중형주는 지난주 최고의 성과를 거두었습니다. 그것들이 당신의 포트폴리오에 있나요? 1. 킹소프트 클라우드(NASDAQ:KC)의 주식은 34.77% 상승했다.

AST 스페이스모바일, 텔레닥 헬스 및 아이렌 등 지난주 최대 상승한 중형주 (2월 3일-2월 7일)

Doctor Looking At Human Teeth X-ray

Earnings

Guidance

Health Care

After-Hours Center

텔레닥 헬스(NYSE:TDOC)의 주가는 회사가 분석가 기대치를 뛰어넘는 3분기 재무 결과를 보고한 후 수요일 시간외 거래에서 11% 이상 급등했다.

텔레닥 헬스의 주식은 예상을 넘는 3분기 실적에 시간외 거래에서 11% 이상 급등

cathie_wood_bz_ark

Markets

$BTC

$ETH

ARKF

ARKK

ARKW

COIN

PINS

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 어드밴스드 마이크로 디바이시스(NASDAQ:AMD), 핀터레스트(NYSE:PINS), 코인베이스 글로벌(NASDAQ:

아크 인베스트가 AMD 주식을 $47.5백만 그리고 핀터레스트 주식을 $12.7백만 매수

Teladoc Health Inc

Shares of Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) have been under pressure since the fourth-quarter earnings release on Feb. 26.
JPMorgan analysts blamed the persistent underperformance of BetterHelp and "a more challenging operating backdrop complicated by renewed macroeconomic concerns.&#8221;
The Teladoc Health Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beea6/lisa-gill">Analyst Lisa Gill</a> reaffirmed a Neutral rating, while reducing the price target from $13 to $11.
The Teladoc Health Thesis: The company is likely to generate Q1 revenues of $617.5 million, versus consensus of $619 million.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The adjusted EBITDA is likely to be $52.8 million, versus consensus of $53 million, she added.
The analyst projected full-year revenue estimate at $2.52 billion. That&#8217;s slightly higher than the consensus of $2,519 million.
The analyst also has a 2026 estimate of $2.56 billion, versus consensus of $2.558 billion.
Gill lowered the <a>adjusted EBITDA estimates for 2025 and 2026 from $311 million to $294 million and from $333 million to $314 million</a>, respectively.
"Our revenue estimates assume Integrated Care growth of +2% and +3% and we model BetterHelp down -7.7% and flat in FY25 and FY26, respectively," she wrote.
While the scale of Teladoc Health platform and the longer-term strategic direction are good, "there is more work to be done," Gill added.
Price Action: Shares of Teladoc Health had risen by 0.06% to $8.62 at the time of publication on Monday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43949618/cisco-and-nvidia-expand-ai-partnership-secure-us-government-authorization-for-cloud-security">Teladoc Health Partners With Eli Liily&#8217;s LillyDirect to Expand Access to Zepbound For Weight Loss</a></li>
</ul>
Photo courtesy of Teladoc
&nbsp;&nbsp;

Analyst Color

Price Target

Reiteration

Analyst Ratings

Teladoc Health Q1 Preview: Analyst Says Strategic Direction Is Good, But There's 'More Work To Be Done'

The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the <a href="https://www.benzinga.com/general/health-care">healthcare supply chain</a>. 
According to Gill, while Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) direct-to-consumer push is putting pressure on compounding pharmacies, it's not a volume shift that should worry pharmaceutical distributors.
LillyDirect's fulfillment model bypasses traditional distributors by shipping straight from Lilly's warehouses via partners like Amazon.com Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Pharmacy and Truepill.
Read Also: <a href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
That means these sales aren't "lost" volume for distributors—they were never in their lane to begin with. Plus, GLP-1 distribution has never been a major profit driver for pharma distributors, so even if some volume moves from compounding pharmacies to LillyDirect, Gill sees minimal impact on their bottom lines.
<h2 class="wp-block-heading">The Numbers Tell The Story</h2>
LillyDirect's GLP-1 play is still a sliver of the market. Even assuming 5% of 2025's estimated 16.2 million Zepbound prescriptions run through LillyDirect, that's just 800,000 scripts &#8211; a drop in the 4.65 billion-prescription U.S. market bucket. 
Translation? This isn't a disruption; it's a strategic skirmish.
<h2 class="wp-block-heading">A Win For Teladoc?</h2>
One clear winner in this shake-up could be Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>). The company is <a href="https://www.benzinga.com/general/health-care/25/03/44170605/teladoc-health-partners-with-eli-liilys-lillydirect-to-expand-access-to-zepbound-for-weight-loss">integrating LillyDirect into its Chronic Care Weight Management program</a>, potentially boosting enrollments. With GLP-1 costs squeezing insurers, this partnership could make Teladoc's weight management offering more attractive to employers looking for coverage alternatives.
LillyDirect may be making waves, but for pharma distributors, it's business as usual. 
As Gill puts it, the GLP-1 cash-pay trend is more about pressuring compounding pharmacies than upending the broader supply chain. 
Investors eyeing big disruptions might want to look elsewhere.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44182967/weight-loss-drugs-soar-while-global-obesity-rates-climb-to-hit-50-of-adults-by-2050-says-new-report">Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report</a></li>
</ul>
Image: Shutterstock

Biotech

Long Ideas

General

AMZN

Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan

Telemedicine operator Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) has entered a pharmacy integration agreement with Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) LillyDirect, a direct-to-consumer pharmacy partner, to streamline access to Zepbound (tirzepatide) for members of Teladoc's Comprehensive <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">Weight Care Program</a>.
Last year, Eli Lilly&nbsp;announced a&nbsp;new&nbsp;website allowing patients to get a prescription for weight loss through a telehealth provider,&nbsp;<a target="_blank" href="https://www.benzinga.com/top-stories/24/05/38798101/pfizer-follows-eli-lillys-footsteps-to-sell-medicines-directly-to-patients" rel="noreferrer noopener">marking an industry first</a>.
The collaboration aims to provide affordable and safe options for individuals without insurance coverage for GLP-1 medications <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44164208/teladoc-health-adds-glp-1-self-pay-option-to-comprehensive-weight-care" rel="noreferrer noopener">used for obesity treatment</a>.
Under the agreement, eligible Teladoc Health members prescribed Zepbound by their provider will have the medication delivered directly to their homes via LillyDirect's digital healthcare platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42970274/teladoc-shares-surge-as-amazon-partnership-fuels-push-for-consumer-centric-healthcare" rel="noreferrer noopener">Teladoc Stock Gains As Amazon Partnership Fuels Push for Consumer-Centric Healthcare</a>
Teladoc's Comprehensive Weight Care and Primary360 teams will have full visibility into each stage of the fulfillment process, including dispensing, shipping, delivery, and refills.
Beyond medication access, Teladoc's Comprehensive Weight Care Program offers a multi-disciplinary approach to obesity management. Members receive support from licensed clinicians with specialized training in obesity medicine, registered dietitians, and health coaches.
Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)&nbsp;recently introduced&nbsp;NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" rel="noreferrer noopener">cash-paying patients</a>.
In February, Teladoc reported fourth-quarter revenue&nbsp;of $640.5 million, down 3% year over year, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43989576/teladoc-health-reports-full-year-and-fourth-quarter-2024-results" rel="noreferrer noopener">consensus estimates</a>.
Price Action: TDOC stock is up 8.02% at $9.75 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44167381/target-hospitality-secures-five-year-lease-with-corecivic-for-dilley-facility-stock-gains" target="_blank" rel="noreferrer noopener">Target Hospitality Secures Five-Year Lease With CoreCivic For Dilley Facility, Stock Gains</a></li>
</ul>
Photo by Ciara Kimsey via Shutterstock

Large Cap

Contracts

Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss

WIIM

Teladoc Health shares are trading higher after the company announced a pharmacy integration agreement with Gifthealth for a GLP-1 self-pay option.

Teladoc Announces Pharmacy Integration Agreement With Gifthealth For  GLP-1 Self-Pay Option

In the latest quarter, 8 analysts provided ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Teladoc Health, revealing an average target of $12.88, a high estimate of $16.00, and a low estimate of $11.50. Surpassing the previous average price target of $12.62, the current average has increased by 2.06%.
<img src="https://www.benzinga.com/files/images/story/2025/1741039222_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Teladoc Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Teladoc Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Teladoc Health: A Closer Look</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>A Deep Dive into Teladoc Health's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Teladoc Health's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -3.03%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -7.56%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.23%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.37%, the company showcases effective utilization of assets.
Debt Management: Teladoc Health's debt-to-equity ratio is below the industry average at 1.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Teladoc Health Stands With Analysts

Goldman Sachs analyst David Roman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and lowers the price target from $16 to $13.

Goldman Sachs Maintains Buy on Teladoc Health, Lowers Price Target to $13

Needham analyst Ryan MacDonald reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) from Hold to Hold.

Needham Reiterates Hold on Teladoc Healthto Hold

Piper Sandler analyst Jessica Tassan maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and lowers the price target from $13 to $12.

Piper Sandler Maintains Overweight on Teladoc Health, Lowers Price Target to $12

Teladoc shares are trading lower following soft Q1 revenue guidance.

Teladoc Sees FY25 Revenue $2.468B-$2.576B vs $2.543B Est., Sees Q1 Revenue $608M-$629M vs $632.911M Est.

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 64.71 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $640.500 million which beat the analyst consensus estimate of $639.552 million by 0.15 percent. This is a 3.03 percent decrease over sales of $660.527 million the same period last year.

Earnings Beats

Earnings Misses

Teladoc Health Q4 2024 GAAP EPS $(0.28) Misses $(0.23) Estimate, Sales $640.500M Beat $639.552M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

<a href="https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/" title="https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/">https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/</a>

Short Sellers

Watching Teladoc Health; 'Blue Orca Capital Is Short Teledoc Health' Issues Report On The Company

Goldman Sachs analyst David Roman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and raises the price target from $14 to $16.

Goldman Sachs Maintains Buy on Teladoc Health, Raises Price Target to $16

6 analysts have shared their evaluations of Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.67, a high estimate of $14.00, and a low estimate of $11.50. This upward trend is evident, with the current average reflecting a 9.22% increase from the previous average price target of $11.60.
<img src="https://www.benzinga.com/files/images/story/2025/1739368852_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Teladoc Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teladoc Health analyst ratings.</a>
<h2>Discovering Teladoc Health: A Closer Look</h2>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
<h3>Teladoc Health: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.99%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teladoc Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.2%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Teladoc Health's ROE stands out, surpassing industry averages. With an impressive ROE of -2.21%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -0.94%. This signifies efficient management of assets and strong financial health.
Debt Management: Teladoc Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Teladoc Health: Insights From 6 Financial Analysts

B of A Securities analyst Allen Lutz maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and raises the price target from $11.5 to $13.5.

B of A Securities Maintains Neutral on Teladoc Health, Raises Price Target to $13.5

Deep-pocketed investors have adopted a bullish approach towards Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TDOC usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Teladoc Health. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 33% bearish. Among these notable options, 2 are puts, totaling $100,220, and 10 are calls, amounting to $394,909.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.5 to $17.5 for Teladoc Health over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Teladoc Health options trades today is 1654.0 with a total volume of 13,969.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Teladoc Health's big money trades within a strike price range of $7.5 to $17.5 over the last 30 days.
<h3>Teladoc Health Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739220323_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$10.00</td>
<td>$90.0K</td>
<td>3.6K</td>
<td>237</td>
</tr>
<tr>
<td>TDOC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$1.85</td>
<td>$1.6</td>
<td>$1.85</td>
<td>$12.50</td>
<td>$74.0K</td>
<td>175</td>
<td>407</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.9</td>
<td>$0.82</td>
<td>$0.88</td>
<td>$14.00</td>
<td>$57.0K</td>
<td>3.7K</td>
<td>2.4K</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$0.92</td>
<td>$0.82</td>
<td>$0.82</td>
<td>$17.50</td>
<td>$41.0K</td>
<td>2.2K</td>
<td>912</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.15</td>
<td>$6.8</td>
<td>$6.89</td>
<td>$10.00</td>
<td>$34.4K</td>
<td>538</td>
<td>93</td>
</tr>
</tbody>
</table>

<h3>About Teladoc Health</h3>
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
Following our analysis of the options activities associated with Teladoc Health, we pivot to a closer look at the company's own performance.
<h3>Current Position of Teladoc Health</h3>
<ul>
<li>With a trading volume of 14,344,358, the price of TDOC is up by 7.14%, reaching $13.88.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 16 days from now.</li>
</ul>
<h3>Expert Opinions on Teladoc Health</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $11.833333333333334.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on Teladoc Health, which currently sits at a price target of $11. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Teladoc Health, maintaining a target price of $12. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Teladoc Health, maintaining a target price of $12. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Teladoc Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Unpacking the Latest Options Trading Trends in Teladoc Health

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Kingsoft Cloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) stock upped 34.77%.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) stock jumped 33.36%. Board member Chris Wright was confirmed as the U.S. Secretary of Energy on February 3, 2025. As a result, he has <a href="https://www.benzinga.com//node/43525625" target="_blank" rel="noreferrer noopener">stepped down from Oklo's Board</a>.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares escalated 30.98% after Cantor Fitzgerald analyst Colin Canfield initiated coverage with an Overweight rating <a href="https://www.benzinga.com/quote/ASTS/analyst-ratings" target="_blank" rel="noreferrer noopener">and price forecast of&nbsp;$30</a>.</li>
<li>VNET Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) shares surged 29.12%.</li>
<li>Teladoc Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares rose 27.46% after the company announced it would acquire Catapult Health in an all-<a href="https://www.benzinga.com//node/43490439" target="_blank" rel="noreferrer noopener">cash $65 million transaction</a>.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) shares were up 25.68%.&nbsp;China recently raised tariffs on certain U.S. imports, and reports suggested that the U.S. is exploring adding Shein and Temu to the ‘forced labor' list.</li>
<li>Magnite, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) stock gained 23.08% last week following a report indicating <a href="https://www.businessinsider.com/elon-musk-x-signs-programmatic-ad-partnership-magnite-2025-2" target="_blank" rel="noreferrer noopener">it signed a partnership</a> with Elon Musk's X, formerly Twitter.</li>
<li>SolarWinds Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) stock grew 23.05% after the company announced that Turn/River Capital would acquire it <a href="https://www.benzinga.com//node/43559292" target="_blank" rel="noreferrer noopener">for &nbsp;$4.4 billion</a>.</li>
<li>Lions Gate Entertainment Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) stock upped 22.68% last week after the company reported better-than-expected Q3 earnings.</li>
<li>IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) shares rose 22.02% last week <a href="https://www.benzinga.com//node/43524343" target="_blank" rel="noreferrer noopener">after reporting it mined</a> 525 Bitcoins (CRYPTO: BTC/USD) in January.</li>
</ol>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43580845/palantir-super-micro-computer-and-spotify-are-among-top-10-large-cap-gainers-last-week-feb-3-feb-7-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Palantir, Super Micro Computer And Spotify Are Among Top 10 Large Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43580887/estee-lauder-moderna-and-paypal-are-among-top-10-large-cap-losers-last-week-feb-3-feb-7-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via ASTS

AST SpaceMobile, Teladoc Health And IREN Are Among Top 10 Mid Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?

Press Releases

Teladoc Health Connects Digital & Community Providers to Deliver Next Generation of Virtually Integrated Care

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

Teladoc Health Adds GLP-1 Self-Pay Option to Comprehensive Weight Care

Artificial Intelligence Influence on Healthcare Industry Reaching All Time Highs for Diagnostics and Treatments

Teladoc Health Expands Connected Care Partnerships

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

Cylinder joins Teladoc Health's Connected Care Program to expand access to virtual digestive care

Carrum Health Selected by Teladoc Health as Centers of Excellence Partner

AI Influence on Medical Diagnostics Generating Billion Dollar Revenues While Growing Adoption Reduces Healthcare Costs

ACON

AVAI

BFRG

TALK

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Claritev Corporation Class A Common Stock

Claritev

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Schrodinger

Simulations Plus

Sophia Genetics

TruBridge

Veeva Systems

VSee Health

Waystar Holding

Goldman Sachs

Piper Sandler

B of A Securities

RBC Capital

Oppenheimer

이 10개 중형주는 지난주 최고의 성과를 거두었습니다. 그것들이 당신의 포트폴리오에 있나요?
1. 킹소프트 클라우드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>)의 주식은 34.77% 상승했다.
2. 오클로(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)의 주식은 33.36% 급등했다. 이사회 멤버인 크리스 라이트(Chris Wright)가 2025년 2월 3일 미국 에너지 장관으로 임명되면서 <a href="https://www.benzinga.com//node/43525625" target="_blank" rel="noreferrer noopener">오클로 이사회에서 사임</a>했다.
3. AST 스페이스모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)의 주식은 캔터 피츠제럴드의 애널리스트 콜린 캔필드(Colin Canfield)가 &#8220;비중확대&#8221; 등급과 <a href="https://www.benzinga.com/quote/ASTS/analyst-ratings" target="_blank" rel="noreferrer noopener">$30의 목표 주가</a>를 제시한 후 30.98% 상승했다.
4. 브이넷 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>)의 주식은 29.12% 급등했다.
5. 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식은 회사가 캐터펄트 헬스(Catapult Health)를 <a href="https://www.benzinga.com//node/43490439" target="_blank" rel="noreferrer noopener">현금</a> 6,500만 달러에 인수할 것이라고 발표한 후 27.46% 상승했다.
6. GDS 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>)의 주식은 25.68% 상승했다. 최근 중국이 일부 미국 수입품에 대한 관세를 인상했으며, 미국이 쉬인과 테무를 &#8216;강제 노동&#8217; 목록에 추가하는 방안을 검토하고 있다는 보도가 나왔다.
7. 매그나이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>)의 주식은 23.08% 상승했다. <a href="https://www.businessinsider.com/elon-musk-x-signs-programmatic-ad-partnership-magnite-2025-2" target="_blank" rel="noreferrer noopener">일론 머스크의 X(구 트위터)</a>와 파트너십을 체결했다는 보도가 나온 후이다.
8. 솔라윈즈 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>)의 주식은 23.05% 상승했습니다. 회사가 턴/리버 캐피털(Turn/River Capital)이 <a href="https://www.benzinga.com//node/43559292" target="_blank" rel="noreferrer noopener">44억 달러에 인수할 것이라고 발표</a>했다.
9. 라이언스게이트 엔터테인먼트 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>)의 주식은 22.68% 상승했다. 회사가 3분기 실적이 예상보다 좋게 나타났다고 보고했다.
10. 아이렌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>)의 주식은 22.02% 상승했다. <a href="https://www.benzinga.com//node/43524343" target="_blank" rel="noreferrer noopener">1월에 525 비트코인</a>(CRYPTO: BTC/USD)를 채굴했다고 보고한 후이다.
다음 읽기:
<ul>
<li></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%BB%B4%ED%93%A8%ED%84%B0-%EB%B0%8F-%EC%8A%A4%ED%8F%AC%ED%8B%B0%ED%8C%8C%EC%9D%B4-%EB%93%B1-%EC%A7%80/" target="_blank" rel="noopener">팔란티어, 슈퍼 마이크로 컴퓨터 및 스포티파이 등 지난주 상승한 10개 대형주 (2월 3일-2월 7일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%90%EC%8A%A4%ED%8B%B0-%EB%A1%9C%EB%8D%94-%EB%AA%A8%EB%8D%94%EB%82%98-%EB%B0%8F-%ED%8E%98%EC%9D%B4%ED%8C%94-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%ED%95%98%EB%9D%BD%ED%95%9C-10%EA%B0%9C%EC%9D%98/" target="_blank" rel="noopener">에스티 로더, 모더나 및 페이팔 등 지난주 하락한 10개의 대형주 (2월 3일-7일)</a></li>
</ul>
사진출처: ASTS
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주가는 회사가 <a href="https://www.benzinga.com/pressreleases/24/10/g41635843/teladoc-health-reports-third-quarter-2024-results" target="_blank" rel="noopener" data-google-interstitial="false">분석가 기대치를 뛰어넘는</a> 3분기 재무 결과를 보고한 후 수요일 시간외 거래에서 11% 이상 급등했다.
<ul>
<li>3분기 매출: 6억 4,051만 달러, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noopener" data-google-interstitial="false">예상치</a>인 6억 3,116만 달러를 상회</li>
</ul>
<ul>
<li>3분기 EPS: 19센트 손실, 예상 손실 27센트보다 개선됨</li>
</ul>
총 매출은 전년 대비 3% 감소했다. 통합 케어 부문 매출은 전년 대비 2% 증가했으며, 베터헬프(BetterHelp) 부문 매출은 10% 감소했다. 미국 매출은 전년 대비 6% 감소했지만, 국제 매출은 15% 증가했다.
3분기 영업 현금 흐름은 1억 1,020만 달러였으며, 이 회사는 분기 동안 7,900만 달러의 잉여 현금 흐름을 생성했다고 밝혔다.
&#8220;2024년을 마무리하면서 우리는 긴급하게 움직이고 있으며, 우리가 제공하는 복잡하고 역동적인 시장에서의 리더십 위치를 보다 효과적으로 활용하기 위해 변화를 만들고 있다. 우리는 앞으로 더 많은 작업이 있으며, 2025년은 중요한 재편성의 해가 될 것이다. 우리의 초점은 일관된 성과를 제공하고 장기적인 주주 가치를 증대시키는 것이다&#8221;라고 텔레닥 헬스의 CEO인 척 디비타(Chuck Divita)가 말했다.
가이던스: 텔레닥은 4분기 통합 케어 부문 매출이 전분기 대비 0%에서 2.5% 증가할 것으로 예상하고 있다. 연간 통합 케어 부문 매출은 저단위에서 중단위 성장할 것으로 예상하고 있다.
TDOC 주가 움직임: 텔레닥의 주식은 수요일 애프터 마켓에서 11.63% 상승하여 9.89달러에 거래되었다.
다음 읽어보기: 
• <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A9%94%ED%83%80-3%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81-%EB%A7%A4%EC%B6%9C-%EB%B0%8F-eps-%EC%98%88%EC%83%81-%EC%83%81%ED%9A%8C-%EC%9D%BC%EC%9D%BC-%ED%99%9C%EC%84%B1-%EC%82%AC%EC%9A%A9%EC%9E%90-5/" target="_blank" rel="noopener">메타 플랫폼스 3분기 실적: 매출 및 EPS 예상치 상회, 일일 활성 사용자 5% 증가, AI 분야 강력한 모멘텀</a>
사진: Teladoc 제공.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Teladoc Health

뉴스

에 대한 최신 뉴스 Teladoc Health (NYSE:TDOC) 주식

일요일, 2월 09, 2025

목요일, 10월 31, 2024

목요일, 8월 01, 2024

수요일, 7월 31, 2024

목요일, 7월 04, 2024

화요일, 7월 02, 2024

목요일, 6월 27, 2024

화요일, 6월 25, 2024

목요일, 6월 13, 2024

화요일, 6월 11, 2024

화요일, 4월 16, 2024

금요일, 4월 12, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌